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which is only testable with longer
periods of follow up. 
As Polman and Killestein note,2 the dif-
ferential anti-inflammatory potency 
of statins should be considered in this
context, since they can also be dose-
dependent. However, experimental
evidence4 suggests that high doses of
statins, which pass the blood-brain bar-
rier, could interfere with neural repair
mechanisms. Hence, we feel that the
widespread use of these drugs in
patients with multiple sclerosis cannot
be recommended until randomised con-
trolled trials have been done to address
these issues. 
*Armando Sena, Rui Pedrosa,
M Graça Morais
arsena@fcm.unl.pt
*Serviço de Neurologia, Hospital dos Capuchos,
Centro Hospitalar de Lisboa, Alameda de Santo
António dos Capuchos, 1169-050 Lisboa, Portugal
(AS, RP); and Departamento de Bioquímica,
Faculdade de Ciências Médicas, Universidade Nova
de Lisboa, Campo Mártires da Pátria, Lisboa,
Portugal (AS, MGM)
1 Vollmer T, Key L, Durkalski V, et al. Oral
simvastatin treatment in relapsing-
remitting multiple sclerosis. Lancet 
2004; 363: 1607–08. 
2 Polman CH, Killestein J. Statins for the
treatment of multiple sclerosis: cautious hope.
Lancet 2004; 363: 1570. 
3 Sena A, Pedrosa R, Morais MG. Therapeutic
potential of lovastatin in multiple sclerosis.
J Neurol 2003; 250: 754–55.
4 Schulz JG, Bösel J, Stoeckel M, Megow D,
Dirnagl U, Endres M. HMG-CoA reductase
inhibition causes neurite loss by interfering
with geranylgeranyl pyrophosphate synthesis.
J Neurochem 2004; 89: 24–32.
Centre of Pharmacovigilance recorded
13 cases of raised creatinine phosphoki-
nase concentrations in individuals
prescribed simvastatin (n=2), atorvas-
tatin (n=6), cerivastatin (n=2),
ﬂuvastatin (n=1), or pravastatin (n=2). In
all cases, doses complied with the mar-
keting authorisations, but the highest
creatinine phosphokinase values arose in
those patients given the highest doses.
Median treatment duration was equiva-
lent to that reported by Vollmer and
colleagues. The French National
Pharmacovigilance Data Base includes
more than 20 cases of  rhabdomyolysis,
occurring during simvastatin use at rec-
ommended dose. 
Although simvastatin, lovastatin, and
mevastatin inhibit proliferation of
peripheral blood mononuclear cells in a
dose-dependent manner they should be
regarded as potentially myotoxic, and
high doses should be used cautiously in
the long term.2 We acknowledge the
treatment breakthrough, but think
muscle enzyme values should be closely
monitored so as to avoid any inappro-
priate and unwanted interruption of
treatment. As statins begin to be avail-
able without prescription in some
countries, this issue is likely to become a
greater concern. 
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Timothy Vollmer and colleagues (May
15, p 1007)1 provide evidence that treat-
ment with 80 mg of simvastatin inhibits
the inflammatory components of mul-
tiple sclerosis. Their study is not,
however, “the ﬁrst to provide some evi-
dence of an effect with a statin in
multiple sclerosis”, as stated by Chris
Polman and Joep Killestein in their
Commentary.2
In 2003, we reported3 the results of an
observational study of seven female
patients who had relapsing-remitting dis-
ease after 1 year of monotherapy with 40
mg of lovastatin. In agreement with
Vollmer and colleagues’ findings, we
noted a reduction in the mean number of
gadolinium (Gd)-enhancing lesions and
no great differences between pretreat-
ment and treatment expanded disability
status scores. Three patients remained
free of relapses, and the mean annual
relapse rate decreased during the year.
However, we did detect new lesions on
T2-weighted images in five patients at
the end of the study. Six people have now
completed 2 years of lovastatin
monotherapy; three patients had relapses
and developed new T2-weighted lesions
during the second year of treatment.
Our results suggest that the reduction
in Gd-enhancing lesions observed by
Vollmer and colleagues after 6 months
of treatment cannot ensure an inhibitory
effect on the progression of the disease,
Timothy Vollmer and colleagues1 report
the effective use of a drug that is gener-
ally considered safe in the treatment of
relapsing-remitting multiple sclerosis,
which is very promising. Although no
serious adverse drug effects arose during
the study, three patients complained of
muscle weakness, one had an increased
creatinine phosphokinase concentra-
tion, and two had abnormal liver-
function test results. This high propor-
tion of adverse effects could be a direct
consequence of the fairly high daily dose
of simvastatin used. We caution against
the chronic administration of such a high
dose.
In 2000 and 2001 (before the cerivas-
tatin withdrawal episode), our Regional
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We appreciate the comments of
Armando Sena, Rui Pedrosa, and Graça
Morais. Our study was an exploratory
study and is suggestive of benefit from
oral simavastatin therapy in patients with
relapsing forms of multiple sclerosis by an
MRI surrogate measure. Their data seem
similar to ours. We agree that neither of
these studies provides adequate support
for the use of statins as a treatment for
multiple sclerosis outside of well-
designed clinical trials. We also agree that
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